Key Takeaways
- • Healius Limited (ASX:HLS) has engaged UBS Securities Australia to explore a potential sale of its Agilex Biolabs standalone business, with multiple private equity firms actively queuing to participate in the process as of May 2026.
- • The Agilex sale represents a strategic asset divestment as Healius restructures its portfolio, following recent earnings downgrades and prior asset sales including the A$965 million (US$657 million) sale of its Lumus Imaging division to Affinity Equity.
- • At least two private equity firms are understood to be in active pursuit of Agilex, signaling strong market appetite for Australia's largest and most technologically advanced pathology/diagnostic services platform.
- • The transaction demonstrates ongoing portfolio rationalization at Healius, with management utilizing strategic divestments to address financial pressures and reposition the company's operational footprint.
Summary
Healius Limited, the Australian healthcare services operator, has initiated a formal sale process for its Agilex Biolabs division through UBS Securities Australia in May 2026. The move represents a significant portfolio restructuring as the company seeks to divest standalone business units and optimize its capital structure. Multiple private equity firms have expressed substantive interest in acquiring Agilex, with at least two firms understood to be actively engaged in the competitive bidding process.
Agilex Biolabs represents Australia's largest and most technologically advanced pathology and diagnostic services platform, acquired by Healius from an entity controlled by Dr. Glenn Haifer. The asset's profile as a market-leading diagnostic provider has attracted considerable institutional investor attention in the private equity community, suggesting the business commands premium valuation multiples within the healthcare services sector.
This divestment is part of a broader strategic reset at Healius, which has faced significant operational headwinds. The company previously slashed its earnings outlook and has already executed major portfolio transactions, including the sale of its Lumus Imaging division to private equity firm Affinity Equity for A$965 million (approximately US$657 million). The succession of asset sales indicates management's strategy to delever the balance sheet, improve financial flexibility, and reframe the company's operational focus following a period of underperformance in its core healthcare services markets.
The competitive nature of the Agilex process—with multiple PE bidders already mobilized—suggests the asset retains significant strategic value and operational upside potential within the hands of specialist healthcare investors. Deal completion timelines and valuation expectations remain undisclosed, though the engagement of UBS as exclusive advisor indicates a structured, professional sales process aligned with institutional investor standards.
Agilex Biolabs represents Australia's largest and most technologically advanced pathology and diagnostic services platform, acquired by Healius from an entity controlled by Dr. Glenn Haifer. The asset's profile as a market-leading diagnostic provider has attracted considerable institutional investor attention in the private equity community, suggesting the business commands premium valuation multiples within the healthcare services sector.
This divestment is part of a broader strategic reset at Healius, which has faced significant operational headwinds. The company previously slashed its earnings outlook and has already executed major portfolio transactions, including the sale of its Lumus Imaging division to private equity firm Affinity Equity for A$965 million (approximately US$657 million). The succession of asset sales indicates management's strategy to delever the balance sheet, improve financial flexibility, and reframe the company's operational focus following a period of underperformance in its core healthcare services markets.
The competitive nature of the Agilex process—with multiple PE bidders already mobilized—suggests the asset retains significant strategic value and operational upside potential within the hands of specialist healthcare investors. Deal completion timelines and valuation expectations remain undisclosed, though the engagement of UBS as exclusive advisor indicates a structured, professional sales process aligned with institutional investor standards.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.